Loading...

LianBio

LIAN•NASDAQ
Healthcare
Biotechnology
$0.32
$-0.03(-8.28%)

LianBio (LIAN) Stock Overview

Explore LianBio’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.6/100

Key Financials

Market Cap34.5M
P/E Ratio-0.31
EPS (TTM)$-0.82
ROE-0.36%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$1.77

LIAN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of LianBio (LIAN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $1.77.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.31 and a market capitalization of 34.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for LIANStats details for LIAN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for LIANAnalyst Recommendations details for LIAN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

CEO

Mr. Adam Leo Stone

Employees

163

Headquarters

103 Carnegie Center Drive, Princeton, NJ

Founded

2021

Frequently Asked Questions

;